After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.
Bioline RX (BLRX) shares are rising as it presents in the Celiac Disease Symposium in Prague this week as well as coverage initiation by analysts at JPMorgan.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.